Bnp Paribas Asset Management Holding S.A. Moon Lake Immunotherapeutics Transaction History
Bnp Paribas Asset Management Holding S.A.
- $41 Billion
- Q2 2025
A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 257 shares of MLTX stock, worth $2,354. This represents 0.0% of its overall portfolio holdings.
Number of Shares
257Holding current value
$2,354% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MLTX
# of Institutions
157Shares Held
54.5MCall Options Held
799KPut Options Held
661K-
Bvf Inc San Francisco, CA19.8MShares$181 Million36.63% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$77.8 Million40.43% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.15MShares$38 Million3.57% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.61MShares$23.9 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.67MShares$15.3 Million0.01% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $338M
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...